Crescent Biopharma Announces Grants of Inducement Awards
Crescent Biopharma, Inc. CBIO
$13.68
▲ +0.22%
(+$0.03)
Open
$13.35
Prev Close
$13.65
Day Range
$13.25 – $14.06
52W Range
$8.72 – $27.41
Market Cap
$507.01M
Beta
1.46
EPS (TTM)
$-7.41
📋 Company Profile
| Industry | Biotechnology |
| Country | US |
| Exchange | NASDAQ NMS - GLOBAL MARKET |
| Currency | USD |
| IPO Date | 2014-01-10 |
| Shares Out. | 37,140,000 |
| Website | crescentbiopharma.com/ ↗ |
| Phone | 16174305595 |
| Employees | 44 |
| Revenue | $0 |
| Gross Profit | $0 |
| Net Income | -$24.8M |
| Free Cash Flow | -$73.6M |
| Total Assets | $182.8M |
| Total Liabilities | $19.5M |
| Equity | $163.3M |
About Crescent Biopharma, Inc.
Crescent Biopharma Inc is a biopharmaceutical company developing novel therapeutics to treat solid tumors, led by CR-001, a proprietary anti-PD-1/anti-VEGF bispecific antibody. Crescent's pipeline product CR-001 has the potential to deliver improved clinical efficacy and safety over pembrolizumab. CR-001 is a new molecular entity designed to replicate the functional properties of ivonescimab, a cooperative bispecific anti-PD-1/anti-VEGF antibody in development by Akeso Biopharma and Summit Therapeutics that delivered improved efficacy in a head-to-head Phase 3 clinical trial versus Keytruda in non-small cell lung cancer. The company focuses on advancing its second and third programs, CR-002 and CR-003, which are antibody drug conjugates (ADCs) against validated oncology targets.
Crescent Biopharma, Inc. is a publicly traded company under the ticker symbol CBIO on the NASDAQ NMS - GLOBAL MARKET, operating in the Biotechnology industry. Quotes and metrics shown here are sourced from public market data and refreshed regularly.
📊 Analyst Ratings
14 analysts (2026-11-01)